title: The costs of future polio risk management policies.
abstract: Decisionmakers need information about the anticipated future costs of maintaining polio eradication as a function of the policy options under consideration. Given the large portfolio of options, we reviewed and synthesized the existing cost data relevant to current policies to provide context for future policies. We model the expected future costs of different strategies for continued vaccination, surveillance, and other costs that require significant potential resource commitments. We estimate the costs of different potential policy portfolios for low-, middle-, and high-income countries to demonstrate the variability in these costs. We estimate that a global transition from routine immunization with oral poliovirus vaccine (OPV) to inactivated poliovirus vaccine (IPV) would increase the costs of managing polio globally, although routine IPV use remains less costly than routine OPV use with supplemental immunization activities. The costs of surveillance and a stockpile, while small compared to routine vaccination costs, represent important expenditures to ensure adequate response to potential outbreaks. The uncertainty and sensitivity analyses highlight important uncertainty in the aggregated costs and demonstrates that the discount rate and uncertainty in price and administration cost of IPV drives the expected incremental cost of routine IPV vs. OPV immunization.
authors.affiliation: Kids Risk Project, Harvard School of Public Health, 677 Huntington Ave., 3rd Floor, Boston, MA 02115, USA.
authors.forename: Radboud J Duintjer
authors.initials: RJ
authors.lastname: Tebbens
authors.forename: Nalinee
authors.initials: N
authors.lastname: Sangrujee
authors.forename: Kimberly M
authors.initials: KM
authors.lastname: Thompson
mesh_terms: D003362:Cost-Benefit Analysis; D004196:Disease Outbreaks / Q000517:prevention & control; D014943:Global Health; D006291:Health Policy; D006801:Humans; D017589:Immunization Programs / Q000191:economics* / Q000639:trends*; D018803:Models, Economic; D011051:Poliomyelitis / Q000517:prevention & control*; D011054:Poliovirus Vaccine, Inactivated / Q000191:economics; D011055:Poliovirus Vaccine, Oral / Q000191:economics; D011634:Public Health; D015203:Reproducibility of Results; D012306:Risk; D012308:Risk Management / Q000191:economics* / Q000379:methods*; D012680:Sensitivity and Specificity
chemical_list: D011054:Poliovirus Vaccine, Inactivated; D011055:Poliovirus Vaccine, Oral